Injectable Drug Delivery Resources

  1. How To Protect A Modern Silicone Oil-Sensitive Biologic Drug For Self-Injection Of 2.25mL 4/25/2023

    A customer experienced expensive project delays when they selected their “tried and tested” large volume, glass syringe system to package a drug to be used in an auto-injector for self-administration.

  2. Containment Solutions To Help Emerging Biologic Companies 3/24/2023

    Set up your small company for long-term success using packaging containment offerings and services to help mitigate risks and speed up your time to market.

  3. Formulation Development From Preclinical To First-In-Human 1/24/2022

    A compound with poor biopharmaceutical properties or improper formulation design could lead to a delay in the project or even program termination.

  4. Compliance Considerations For Emergency-Use Delivery Systems 5/2/2022

    Because auto-injectors are typically the delivery device of choice for emergency medications, they come with increased scrutiny from regulatory bodies regarding their safety and effectiveness.

  5. CDMO Collaboration: The Foundation For Sterile Injectable Success

    Discover how an experienced and adaptable CDMO can provide tailored support to biotechs and pharma companies of all sizes, ensuring seamless sterile injectable development and manufacturing without compromising quality or safety.

  6. The Future Of CDMOs: Aseptic Filling Solutions For Growth And Innovation 9/15/2023

    The rapid rise of highly targeted cell and gene treatments requiring small batch production necessitates a new path forward for biologics manufacturing and directly impacts the CMO/CDMO landscape.

  7. Moving From Vial Systems To Prefilled Syringes And Autoinjector Systems

    Moving from vial systems to prefilled syringes and autoinjector systems requires patient and caregiver needs, drug product requirements, system components, and performance.

  8. 4 Factors Affecting Solubility Of Drugs 2/28/2022

    Improper drug solubility can lead to suboptimal drug delivery and absorption, resulting in ineffective drug efficacy and side effects, so solubility must be evaluated in the early stages of drug discovery.

  9. From Regulators To PUPSIT: Notes On Annex 1 Revision Implementation 5/26/2023

    Kevin Smyth, a biochemical engineer with 30 years of experience in the pharmaceutical industry, offers insights and expertise in working with firms to understand what regulators seek to meet new standards.

  10. Supporting The Unique Needs Of Your Sterile Injectable

    Leveraging the experience and specialized technology of a reliable CDMO partner is essential to ensure your sterile injectable therapeutic's safety and quality while delivering at speed.